Category Archives: Patently BIOtech

Prior User Rights and Trade Secrets

Research

By Joe Allen, President, Allen and Associates One theme of the day is the cloud of uncertainity overhanging the US patent system. This was underscored in the Prior User Rights and Trade Secrets session at the 2012 BIO International Convention as well. The new prior user rights defense which came into effect with enactment of the America Invents Act (AIA) was very differently viewed by the small biotech company perspective given by Mary Ann Dillahunty (Oncolytics Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Recent Developments in Patentability: Prometheus and Myriad

supreme-court

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at the 2012 BIO International Convention was a very lively panel discussion on two cases that have set the life science industry on edge. The discussion presented an appropriate diversity of views as experts struggle with how broadly these cases should be interpreted. Briefly, the unanimous decision by the Supreme Court overtuning a decision upholding the Prometheus patents by the Court Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

From Bench to Bedside in a Bioeconomy

lab_tech02-btn

By Joe Allen, President, Allen and Associates It’s a sign of a well crafted program when the closing panel reinforces the opening speaker. Boston University President Robert Brown kicked off the afternoon at the Translational Research Forum at the 2012 BIO International Convention by showing how the old linear model of product development crafted after World War II no longer applies. The closing industry panel aptly remarked that a struggling economy has brought the public and private Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Measuring the Impact of Innovation

USPTO

By Joe Allen, President, Allen and Associates It’s always an indication of interest and importance in a topic when a panel draws a standing room only crowd. And that was the case with the Measuring the Impacts of Innovation: What is the Future of Tech Transfer? session at the 2012 BIO International Convention. The panel focused on the need to help policy makers, institutions and the public identify appropriate measures for how publicly funded R&D Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Gene Patent Discussion Should Include Industrial, Environmental, & Ag Biotech

myriad-more

Twenty-three industrial and agricultural biotech companies, ranging from development-stage businesses to all of the largest players in the field, sent a letter to the Solicitor General expressing concern over the pending appeal in the Myriad “gene patents” case.  The companies wrote the letter to correct the myopic view that this case is only about human genetic diagnostics. The case could potentially adversely impact agricultural and industrial biotechnology, whose activities are far removed from the clinical Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,